{
    "Trade/Device Name(s)": [
        "Lithium test system",
        "Lithium"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K063684",
    "Predicate Device Reference 510(k) Number(s)": [
        "K963627"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NDW",
        "JIX"
    ],
    "Summary Letter Date": "March 7, 2008",
    "Summary Letter Received Date": "March 14, 2008",
    "Submission Date": "January 14, 2008",
    "Regulation Number(s)": [
        "21 CFR 862.3560"
    ],
    "Regulation Name(s)": [
        "Lithium test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "tdm"
    ],
    "Analyte(s)": [
        "Lithium"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Roche/Hitachi cobas c systems",
        "cobas c501"
    ],
    "Method(s)/Technology(ies)": [
        "Colorimetric test"
    ],
    "Methodologies": [
        "Colorimetric assay"
    ],
    "Submission Type(s)": [
        "Reagent system",
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Roche Diagnostics cobas c501 Lithium test system for quantitative lithium determination in serum and plasma",
    "Indications for Use Summary": "In vitro test for quantitative determination of lithium in human serum and plasma on Roche/Hitachi cobas c systems, used as an aid in management of patients taking lithium for mental disturbances such as bipolar disorder",
    "fda_folder": "Toxicology"
}